Tempus AI lifts 2026 revenue outlook

Tempus AI

05/05/2026 21:10

Overview

U.S. AI precision medicine firm's Q1 revenue grew 36% yr/yr, slightly beating analyst expectations

Adjusted EBITDA loss for Q1 narrowed and beat analyst estimates

Company raised full-year 2026 revenue guidance to $1.59-$1.60 bln

Outlook

Tempus AI raises 2026 revenue guidance to $1.59-$1.60 bln

Company continues to expect 2026 Adjusted EBITDA of ~$65 mln

Tempus AI says strong demand for AI-driven diagnostics and data modeling expected to continue

Result Drivers

ONCOLOGY & HEREDITARY VOLUME - Diagnostics revenue grew 34.7% yr/yr, driven by 28% Oncology volume growth and 54% Hereditary volume growth (7% after adjusting for Ambry acquisition timing)

MRD TESTING - MRD test volume rose ~500% yr/yr to ~6,500 tests, supporting Diagnostics segment growth

DATA & APPLICATIONS MOMENTUM - Data and Applications revenue grew 40.5% yr/yr, with Insights (data licensing and modeling) up 44.1%

Company press release: ID:nBw1ydm4Qa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$348.12 mln
$345.46 mln (15 Analysts)
Q1 Net Income
-$125.92 mln
Q1 Adjusted EBITDA
Beat
-$2.83 mln
-$4.74 mln (9 Analysts)
Q1 Income from Operations
-$84.71 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tempus AI Inc is $80.00, about 43.3% above its May 4 closing price of $55.81

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)